Autopsy report · NCT01522196

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

“change in company plans”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 month before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Anthera Pharmaceuticals

Sponsor type

Industry

Conditions

Sickle Cell Disease; Vaso-occlusive Crisis

Interventions

Varespladib; Placebo (Normal Saline)

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS
  “Change in development plan” (75% match in meaning)
• Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease
  “Change in company strategy.” (70% match in meaning)
• A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
  “Development plan change” (69% match in meaning)
• Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
  “Change in company priorities” (66% match in meaning)
• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.